A study published in the Journal of Gastroenterology and Hepatology found regular coffee consumption seems to delay disease progression in alcoholic liver disease and primary sclerosing cholangitis patients with end-stage liver disease and seems to increase long-term survival following liver transplantation, as reported by MPR.
Kilian Friedrich, MD, from the University Hospital of Heidelberg in German, and colleagues assessed coffee consumption habits in 379 patients with ESLD awaiting liver transplantation and 260 patients after liver transplantation.
Here are five points:
1. Researchers found 195 patients with ESLD consumed coffee on a daily basis, while 184 patients did not.
2. Actuarial survival was lowered among non-coffee drinkers compared to coffee drinkers.
3. The rate of survival of patients with ALD and PSC increased with coffee intake, but did not affect patients with chronic viral hepatitis or other liver disease entities.
4. Coffee consumption of PSC and ALD patients remained an independent risk factor in multivariate analysis, along with Model for End-Stage Liver Disease score.
5. Long-term survival improved among coffee drinkers following liver transplantation versus non-coffee drinkers.